Clinical Lipidology. Edition: 3

SECTION I INTRODUCTION/BASIC MECHANISMS

1 Overview of Lipids and Atherosclerosis

SECTION II RISK ASSESSMENT

2 Overview of Risk Assessment

3 Measurement of Low- Density Lipoprotein

Cholesterol, Non-High- Density Lipoprotein

Cholesterol, Apolipoprotein B, and

Low- Density Lipoprotein Particle

Concentration

4 Triglycerides, Triglyceride- Rich Lipoproteins,

and High- Density Lipoprotein in Coronary

Heart Disease Risk Assessment

5 Lipoprotein(a) in Cardiovascular Risk

Assessment

6 Clinical Evaluation for Genetic Testing and

Secondary Causes of Dyslipidemia

7 Polygenic Risk Scores

8 High- Sensitivity C- Reactive Protein

9 Emerging Assays for Risk Assessment

10 Imaging Atherosclerosis for Risk

Stratifi cation: Cardiac Computed

Tomography and Carotid Ultrasound

SECTION III THERAPY

11 Overview of General Approach to

Management of Dyslipidemias

12 Treatment Guidelines Overview: American

Heart Association/American College of

Cardiology/Multisociety Guideline and

Updates

13 Treatment Guidelines Overview:

European Society of Cardiology/European

Atherosclerosis Society Guidelines

14 Dietary Patterns for the Prevention and

Treatment of Cardiovascular Disease

15 Updated Clinical Guide to Exercise and

Lipids

16 Obesity, Lipids, and Cardiovascular Disease

17 Statins

18 Cholesterol Absorption Inhibitors

19 Omega- 3 Fatty Acids

20 Proprotein Convertase Subtilisin/Kexin Type

9 Inhibition

21 Inclisiran

22 Bempedoic Acid

23 Pemafi brate: A New Selective Peroxisome

Proliferator-Activated Receptor- _

Modulator for Hypertriglyceridemia

Management

24 Anti- inflammatory Therapy for

Cardiovascular Disease

25 Nutraceuticals and Functional Foods for

Cholesterol Reduction

SECTION IV NEW AND EVOLVING THERAPEUTIC

TARGETS AND PLATFORMS

26 Evolving Therapeutic Targets:

Lipoprotein(a)

27 Inhibition of ANGPTL3 as a Target for

Treating Dyslipidemias

28 Evolving Therapeutic Targets:

Apolipoprotein C- III

29 Evolving Therapeutic Targets: Cholesteryl

Ester Transfer Protein Inhibition

30 Gene Therapy and Therapeutic Genome

Editing in Liver for Lipid Disorders

SECTION V SPECIAL PATIENT POPULATIONS

31 Special Patient Populations: Diabetes and

Metabolic Syndrome

32 Special Patient Populations: Women and

Older Adults

33 Special Patient Populations: Children and

Adolescents

34 Special Patient Populations: Familial

Hypercholesterolemia and Other Severe

Hypercholesterolemias

35 Special Patient Populations: Treatment of

Familial Chylomicronemia Syndrome and

Sustained Chylomicronemia

36 Special Patient Populations: Acute Coronary

Syndromes

37 Special Patient Populations: Transplant

Recipients

38 Special Populations: Chronic Kidney

Disease

39 Special Patient Populations: Lipid

Abnormalities in High- Risk Racial/Ethnic

Groups

40 Persons With Human Immunodeficiency

Virus